CA2509077C - Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease - Google Patents

Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease Download PDF

Info

Publication number
CA2509077C
CA2509077C CA2509077A CA2509077A CA2509077C CA 2509077 C CA2509077 C CA 2509077C CA 2509077 A CA2509077 A CA 2509077A CA 2509077 A CA2509077 A CA 2509077A CA 2509077 C CA2509077 C CA 2509077C
Authority
CA
Canada
Prior art keywords
rapamycin
stent
drug
coating
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2509077A
Other languages
English (en)
French (fr)
Other versions
CA2509077A1 (en
Inventor
Robert Falotico
Jonathon Z. Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardinal Health 529 LLC
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Publication of CA2509077A1 publication Critical patent/CA2509077A1/en
Application granted granted Critical
Publication of CA2509077C publication Critical patent/CA2509077C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
CA2509077A 2004-06-02 2005-06-02 Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease Expired - Lifetime CA2509077C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/858,954 2004-06-02
US10/858,954 US7989490B2 (en) 2004-06-02 2004-06-02 Injectable formulations of taxanes for cad treatment

Publications (2)

Publication Number Publication Date
CA2509077A1 CA2509077A1 (en) 2005-12-02
CA2509077C true CA2509077C (en) 2015-03-17

Family

ID=35124435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2509077A Expired - Lifetime CA2509077C (en) 2004-06-02 2005-06-02 Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease

Country Status (4)

Country Link
US (2) US7989490B2 (enExample)
EP (1) EP1618879B1 (enExample)
JP (1) JP5615474B2 (enExample)
CA (1) CA2509077C (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
DE69634278T2 (de) 1996-02-28 2006-01-05 Bard Peripheral Vascular, Inc., Tempe Mit einem flansch ausgestattetes transplantat für eine end-zu-seit-anastomose
GB9709967D0 (en) 1997-05-17 1997-07-09 Harris Peter L Prosthetic grafts
US7244441B2 (en) * 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8024036B2 (en) 2007-03-19 2011-09-20 The Invention Science Fund I, Llc Lumen-traveling biological interface device and method of use
US8092549B2 (en) 2004-09-24 2012-01-10 The Invention Science Fund I, Llc Ciliated stent-like-system
US7850676B2 (en) 2004-04-19 2010-12-14 The Invention Science Fund I, Llc System with a reservoir for perfusion management
US8337482B2 (en) 2004-04-19 2012-12-25 The Invention Science Fund I, Llc System for perfusion management
US8361013B2 (en) 2004-04-19 2013-01-29 The Invention Science Fund I, Llc Telescoping perfusion management system
US8000784B2 (en) 2004-04-19 2011-08-16 The Invention Science Fund I, Llc Lumen-traveling device
US9011329B2 (en) 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US7998060B2 (en) 2004-04-19 2011-08-16 The Invention Science Fund I, Llc Lumen-traveling delivery device
US8353896B2 (en) 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
US9801527B2 (en) 2004-04-19 2017-10-31 Gearbox, Llc Lumen-traveling biological interface device
US11207457B2 (en) * 2004-08-27 2021-12-28 Edwards Lifesciences Corporation Device and method for establishing an artificial arterio-venous fistula
WO2006113492A2 (en) 2005-04-14 2006-10-26 President And Fellows Of Harvard College Adjustable solubility in sacrificial layers for microfabrication
US10076641B2 (en) 2005-05-11 2018-09-18 The Spectranetics Corporation Methods and systems for delivering substances into luminal walls
US8709069B2 (en) 2005-07-01 2014-04-29 C. R. Bard, Inc. Flanged graft with trim lines
US7723422B2 (en) * 2005-12-23 2010-05-25 Boston Scientific Scimed, Inc. Functionalized block copolymers
DK1984009T3 (da) * 2006-01-18 2013-01-28 Qps Llc Farmaceutiske sammensætninger med forbedret stabilitet
US20120035438A1 (en) 2006-04-12 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Path selection by a lumen traveling device in a body tub tree based on previous path
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US20100280598A1 (en) * 2007-12-27 2010-11-04 C.R. Bard, Inc. Vascular graft prosthesis having a reinforced margin for enhanced anastomosis
US20090187238A1 (en) * 2008-01-17 2009-07-23 Boston Scientific Scimed, Inc. System and method for deploying self-expandable medical device with coating
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
CA2743027C (en) 2008-11-07 2016-04-12 Insuline Medical Ltd. Device and method for drug delivery
AU2010239605B2 (en) * 2009-04-20 2014-06-26 Rox Medical, Inc. Device and method for establishing an artificial arterio-venous fistula
US9283305B2 (en) 2009-07-09 2016-03-15 Medtronic Vascular, Inc. Hollow tubular drug eluting medical devices
US8460745B2 (en) 2009-09-20 2013-06-11 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8828474B2 (en) 2009-09-20 2014-09-09 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8678046B2 (en) 2009-09-20 2014-03-25 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US20110070358A1 (en) 2009-09-20 2011-03-24 Medtronic Vascular, Inc. Method of forming hollow tubular drug eluting medical devices
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
EP2380604A1 (en) 2010-04-19 2011-10-26 InnoRa Gmbh Improved coating formulations for scoring or cutting balloon catheters
US8632846B2 (en) 2010-09-17 2014-01-21 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8333801B2 (en) 2010-09-17 2012-12-18 Medtronic Vascular, Inc. Method of Forming a Drug-Eluting Medical Device
US8616040B2 (en) 2010-09-17 2013-12-31 Medtronic Vascular, Inc. Method of forming a drug-eluting medical device
US20120303115A1 (en) * 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9878486B2 (en) * 2011-12-22 2018-01-30 Baker Hughes, A Ge Company, Llc High flash point fluids for in situ plasticization of polymers
US9486340B2 (en) 2013-03-14 2016-11-08 Medtronic Vascular, Inc. Method for manufacturing a stent and stent manufactured thereby
WO2014182542A1 (en) 2013-05-06 2014-11-13 Abbott Cardiovascular Systems Inc. A hollow stent filled with a therapeutic agent formulation
CA2998170C (en) 2015-09-15 2023-10-03 Savage Medical, Inc. Devices and methods for anchoring a sheath in a tissue cavity
TWI838700B (zh) 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US11504362B2 (en) 2017-06-09 2022-11-22 Exelixis, Inc. Liquid dosage forms to treat cancer
CN114568015A (zh) 2019-08-22 2022-05-31 爱德华兹生命科学公司 穿刺针
AU2020383327A1 (en) 2019-11-14 2022-06-02 Edwards Lifesciences Corporation Transcatheter medical implant delivery
CN114748644B (zh) * 2022-05-20 2023-08-18 齐齐哈尔大学 一种以zif-8为基质的藻蓝蛋白分子印迹药物载体的制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3959078A (en) * 1973-05-18 1976-05-25 Midwest Research Institute Enzyme immobilization with a thermochemical-photochemical bifunctional agent
SU1088712A1 (ru) * 1979-11-14 1984-04-30 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Аппарат дл циркул рного сшивани кровеносных сосудов
US4368736A (en) * 1980-11-17 1983-01-18 Kaster Robert L Anastomotic fitting
US4366819A (en) * 1980-11-17 1983-01-04 Kaster Robert L Anastomotic fitting
SE431609B (sv) * 1982-06-24 1984-02-20 Unilink Ab Kirurgiskt instrument for astadkommande av anastomos och festelement herfor
US4917091A (en) * 1982-06-24 1990-04-17 Unilink Ab Annular fastening means
US4722906A (en) * 1982-09-29 1988-02-02 Bio-Metric Systems, Inc. Binding reagents and methods
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5234447A (en) * 1990-08-28 1993-08-10 Robert L. Kaster Side-to-end vascular anastomotic staple apparatus
TW197439B (enExample) * 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
CA2071160A1 (en) * 1991-07-31 1993-02-01 Vittorio Farina Asymmetric synthesis of taxol side chain
SG46582A1 (en) * 1991-09-23 1998-02-20 Univ Florida State 10-Desacetoxytaxol derivatives
US5283253A (en) * 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5440056A (en) * 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
EP0642586A4 (en) 1992-05-21 1995-11-29 Penn State Res Found CULTURAL -i (TAXUS) FABRIC AS A SOURCE OF TAXOL, RELATED TAXANS AND OTHER NEW ANTI-TUMOR / ANTI-VIRAL SUBSTANCES (01/20/94).
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5274137A (en) * 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5202448A (en) * 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
WO1994005282A1 (en) * 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2145190A1 (en) * 1992-09-22 1994-03-31 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Use of taxol for treating lymphomas and breast cancer
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5411984A (en) * 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5279949A (en) * 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5308641A (en) * 1993-01-19 1994-05-03 Medtronic, Inc. Biocompatibility of solid surfaces
US5229172A (en) * 1993-01-19 1993-07-20 Medtronic, Inc. Modification of polymeric surface by graft polymerization
US5350800A (en) * 1993-01-19 1994-09-27 Medtronic, Inc. Method for improving the biocompatibility of solid surfaces
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
AU6361294A (en) 1993-03-09 1994-09-26 Enzon, Inc. Taxol-based compositions with enhanced bioactivity
TW467896B (en) * 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5395850A (en) * 1994-03-10 1995-03-07 Bristol-Myers Squibb Company 6,7-epoxy paclitaxels
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5924997A (en) * 1996-07-29 1999-07-20 Campbell; Thomas Henderson Catheter and method for the thermal mapping of hot spots in vascular lesions of the human body
US6245026B1 (en) * 1996-07-29 2001-06-12 Farallon Medsystems, Inc. Thermography catheter
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
AU6178198A (en) * 1997-03-07 1998-09-22 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6425898B1 (en) * 1998-03-13 2002-07-30 Cordis Corporation Delivery apparatus for a self-expanding stent
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
WO2000071163A1 (en) 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
EP1315484A1 (en) * 2000-03-24 2003-06-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CN1615130A (zh) 2001-12-28 2005-05-11 Ivax研究公司 基于紫杉烷的组合物及使用方法
IL163808A0 (en) * 2002-03-01 2005-12-18 Yissum Res Dev Co Self emulsifying drug delivery systems for poorly soluble drugs
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US7438722B1 (en) * 2002-09-20 2008-10-21 Advanced Cardiovascular Systems, Inc. Method for treatment of restenosis
WO2004091506A2 (en) 2003-04-10 2004-10-28 Ivax Research, Inc. Taxane-based compositions and methods of use
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment

Also Published As

Publication number Publication date
JP2005343897A (ja) 2005-12-15
CA2509077A1 (en) 2005-12-02
JP5615474B2 (ja) 2014-10-29
US20050272806A1 (en) 2005-12-08
EP1618879B1 (en) 2013-02-27
EP1618879A1 (en) 2006-01-25
US7989490B2 (en) 2011-08-02
US9402804B2 (en) 2016-08-02
US20110245332A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
CA2509077C (en) Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease
US8182527B2 (en) Heparin barrier coating for controlled drug release
US8007737B2 (en) Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
CA2660325C (en) Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7932265B2 (en) Solution formulations of sirolimus and its analogs for CAD treatment
US7947302B2 (en) Antithrombotic coating for drug eluting medical devices
US8747881B2 (en) Intraluminal medical devices in combination with therapeutic agents
US8784860B2 (en) Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
EP1772115A1 (en) Intraluminal device and therapeutic agent combination for treating aneurysmal disease
EP1586337A2 (en) The local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
US20050249776A1 (en) Coated aneurysmal repair device
US20070026042A1 (en) System for treating aneurysmal disease
US8506984B2 (en) Therapeutic agent elution control process

Legal Events

Date Code Title Description
EEER Examination request